We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

92 hedge funds and large institutions have $676M invested in Aimmune Therapeutics in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

230% more call options, than puts

Call options by funds: $684K | Put options by funds: $207K

100% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 18

49% more capital invested

Capital invested by funds: $453M → $676M (+$224M)

24% more funds holding

Funds holding: 74 → 92 (+18)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
92
Holders Change
+18
Holders Change %
+24.32%
% of All Funds
2.3%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
23
Increased
36
Reduced
18
Closed
5
Calls
$684K
Puts
$207K
Net Calls
+$477K
Net Calls Change
+$490K

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$14.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$8.33M
3
BIT
BlackRock Institutional Trust
California
+$6.72M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.39M
5
EA
Emerald Advisers
Pennsylvania
+$6.31M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$12.6M
2
TG
TLP Group
Illinois
-$8.92M
3
FCMI
Foresite Capital Management II
California
-$2.7M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.56M
5
CCI
Columbus Circle Investors
-$918K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$4.02M +$123K +6,028 +3%
ERSOT
27
Employees Retirement System of Texas
Texas
$3.98M +$3.98M +194,804 New
EI
28
EAM Investors
California
$3.39M +$3.39M +165,625 New
Bank of America
29
Bank of America
North Carolina
$2.96M +$165K +8,060 +6%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.79M +$932K +45,575 +50%
American Century Companies
31
American Century Companies
Missouri
$2.22M +$136K +6,659 +7%
Deutsche Bank
32
Deutsche Bank
Germany
$2.13M +$457K +22,346 +27%
Renaissance Technologies
33
Renaissance Technologies
New York
$2.1M +$2.1M +102,700 New
Public Employees Retirement Association of Colorado
34
Public Employees Retirement Association of Colorado
Colorado
$1.99M +$1.99M +97,403 New
BIM
35
BlackRock Investment Management
Delaware
$1.96M -$2.64K -129 -0.1%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$1.71M +$1.7M +83,336 New
Charles Schwab
37
Charles Schwab
California
$1.68M +$88.1K +4,312 +6%
AG
38
Artal Group
Luxembourg
$1.67M +$1.67M +81,600 New
TCIM
39
TIAA CREF Investment Management
New York
$1.62M -$92.2K -4,510 -5%
PPA
40
Parametric Portfolio Associates
Washington
$1.5M +$506K +24,733 +51%
Wells Fargo
41
Wells Fargo
California
$1.3M +$179K +8,755 +16%
Norges Bank
42
Norges Bank
Norway
$1.26M +$1.26M +61,500 New
Ameriprise
43
Ameriprise
Minnesota
$1.14M +$1.14M +55,773 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.11M -$26.6K -1,300 -2%
Citigroup
45
Citigroup
New York
$1.01M +$951K +46,511 +1,663%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$922K +$922K +45,094 New
TA
47
Teachers Advisors
New York
$884K +$21K +1,025 +2%
Goldman Sachs
48
Goldman Sachs
New York
$863K +$863K +42,216 New
AA
49
ALPS Advisors
Colorado
$833K -$269K -13,137 -24%
PMLI
50
Penn Mutual Life Insurance
Pennsylvania
$797K +$797K +39,000 New
1
2
3 4

AIMT Hedge Fund Activity: Q4 2016 in Review

92 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2016, worth a combined $676M — up 49% from $453M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AIMT positions and 5 closed out — a net gain of 18 holders — while 36 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $14.2M. The largest seller was RA Capital Management, cutting an estimated $12.6M.

  • 92 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2016, up from 74 in Q3 2016.
  • Funds reported $676M of Aimmune Therapeutics stock for Q4 2016, up 49% quarter-over-quarter.
  • 23 funds opened new Aimmune Therapeutics positions in Q4 2016 and 5 closed out, a net change of +18 holders.
  • The largest Aimmune Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $14.2M added.
  • The largest Aimmune Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2016.